Campbell & Co Investment Adviser’s Xenon Pharmaceuticals XENE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$913K	Sell	15,134 -3,022	-17%	-$168K	0.05%	574
2026 Q1	$1.06M	Buy	18,156 +2,051	+13%	+$94.5K	0.06%	492
2025 Q4	$722K	Sell	16,105 -12,564	-44%	-$528K	0.03%	694
2025 Q3	$1.15M	Buy	+28,669	New	+$1.01M	0.09%	363
2024 Q4	–	Sell	-7,339	Closed	-$289K	–	1417
2024 Q3	$289K	Sell	7,339 -16,721	-69%	-$674K	0.02%	916
2024 Q2	$938K	Buy	+24,060	New	+$962K	0.08%	391
2024 Q1	–	Sell	-17,973	Closed	-$828K	–	1409
2023 Q4	$828K	Buy	+17,973	New	+$635K	0.07%	471

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Campbell & Co Investment Adviser's XENE Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $168K and leaving 15,134 shares worth $913K. The position accounts for 0.05% of the portfolio, ranked #574.

Campbell & Co Investment Adviser first reported a position in XENE in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.15M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Campbell & Co Investment Adviser held 15,134 shares of Xenon Pharmaceuticals worth $913K as of Q2 2026.
Campbell & Co Investment Adviser sold 3,022 Xenon Pharmaceuticals shares in Q2 2026, an estimated $168K.
Xenon Pharmaceuticals made up 0.05% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #574 holding.
Campbell & Co Investment Adviser first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
Campbell & Co Investment Adviser's Xenon Pharmaceuticals position peaked at $1.15M in Q3 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.